These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34986867)

  • 21. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M
    Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
    Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
    Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
    Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
    J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
    Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
    J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
    Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
    Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating CD8 lymphocytes predict response to atezolizumab-bevacizumab in hepatocellular carcinoma.
    Gramantieri L; Suzzi F; Bassi C; D'Abundo L; Tovoli F; Bruccoleri M; Marseglia M; Alimenti E; Fornari F; Negrini M; Iavarone M; Piscaglia F; Giovannini C
    Eur J Immunol; 2024 Feb; 54(2):e2350637. PubMed ID: 37990855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of CD8
    Li J; Chen H; Bai L; Tang H
    BMC Cancer; 2024 Jan; 24(1):53. PubMed ID: 38200408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
    Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
    Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
    Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.
    Xu LX; He MH; Dai ZH; Yu J; Wang JG; Li XC; Jiang BB; Ke ZF; Su TH; Peng ZW; Guo Y; Chen ZB; Chen SL; Peng S; Kuang M
    Ann Oncol; 2019 Jun; 30(6):990-997. PubMed ID: 30916311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.